Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections A Road Map for Research
Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections A Road Map for Research
复制标题
DOI：
10.1164/rccm.201807-1273pp
复制
发表时间：
2019-04-15
影响因子：
24.7
通讯作者：
Zelazny, Adrian M.
中科院分区：
文献类型：
--
作者：
Daniel-Wayman, Shelby;Abate, Getahun;Zelazny, Adrian M.
非结核分支杆菌肺病（NTM PD）可能是慢性的，需要数月至数年的漫长而复杂的治疗方案。治疗后，患者往往再次感染，病情复发。据估计，2010年美国的NTM PD患病率为86，000例，超过了肺结核（TB），2016年为9，272例，并呈下降趋势;自20世纪90年代中期以来，在美国和加拿大不同人群中进行的多项研究表明患病率不断增加（1）。在澳大利亚、亚洲和欧洲也记录了NTM PD的患病率增加（2）。临床护理标准（3）将受益于对照临床试验。为了确定诊断，治疗和预防NTM PD的关键差距，国家过敏和变态反应疾病研究所于2017年9月26日召开了一次研讨会，汇集了分枝杆菌疾病的不同专家。本报告总结了宿主-病原体相互作用、分子流行病学和诊断学以及疫苗/治疗学中的关键问题。这些关键的重点领域可能有助于指导生物医学研究工作进入这一日益增长的关注。
Nontuberculous mycobacterial pulmonary disease (NTM PD) may be chronic, requiring lengthy and complex regimens over many months to years. After treatment, patients are often reinfected, with disease recurrence. NTM PD prevalence was estimated at 86,000 cases in the United States in 2010, surpassing pulmonary tuberculosis (TB), which was 9,272 in 2016 and declining; multiple studies in different US and Canadian populations have indicated increasing prevalence since the mid-1990s (1). Increasing prevalence of NTM PD has also been documented in Australia, Asia, and Europe (2). Clinical care standards (3) would benefit from controlled clinical trials. To identify critical gaps in diagnosis, treatment, and prevention of NTM PD, the National Institute of Allergy and InfectiousDiseases convened a workshop on September 26, 2017, bringing together diverse experts in mycobacterial disease. This report summarizes the key questions in host–pathogen interactions, molecular epidemiology and diagnostics, and vaccine/therapeutics. These key focus areas may help guide biomedical research efforts into this growing concern.